Patents Issued in May 28, 2020
  • PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND CO-CRYSTALS THEREOF
    Publication number: 20200165269
    Abstract: The present invention relates to processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives which are useful as a Janus kinase (JAK) inhibitor, co-crystals thereof, processes for preparing the co-crystals, and processes for purifying 7H-pyrrolo[2,3-d]pyrimidine derivatives by employing the co-crystals. The present invention provides, for example, a process for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile by employing a co-crystal of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile with 3,5-dimethylpyrazole.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 28, 2020
    Inventor: Takahisa Shimazaki
  • Low Halide Lanthanum Precursors For Vapor Deposition
    Publication number: 20200165270
    Abstract: Lanthanide compounds for vapor deposition having ?50.0 ppm, ?30.0 ppm, or ?10.0 ppm of all halide impurity combined is provided. The purification systems and methods are also provided.
    Type: Application
    Filed: November 15, 2019
    Publication date: May 28, 2020
    Applicant: Versum Materials US, LLC
    Inventors: Neil Osterwalder, Sergei V. Ivanov
  • NOVEL ORGANOBORANES USEFUL AS ELECTROLYTES FOR LITHIUM BATTERIES
    Publication number: 20200165271
    Abstract: Disclosed are novel organoborane compositions of Formula (I), (II) or (III), wherein R1, R2, R3, R?, R?, n, n?, n?, m, m?, and m? are defined hereinabove. Also disclosed is a method of using said compositions for electrolytic media in lithium rechargeable batteries, including lithium-ion or lithium-air rechargeable batteries. Also disclosed are compositions containing said Formula (I), (II) and (III) compounds with lithium salts, useful as electrolytic media or matrices.
    Type: Application
    Filed: November 27, 2018
    Publication date: May 28, 2020
    Inventors: Ishrat Khan, Ahmed Alzharani, Amal Al-abdulrahman, Rasha Alshahrani
  • BORATE COMPOUND, AND SYNTHESIS METHOD THEREFOR AND USES THEREOF
    Publication number: 20200165272
    Abstract: A borate compound serving as a proteasome inhibitor, a preparation method for the borate compound and uses thereof.
    Type: Application
    Filed: July 27, 2018
    Publication date: May 28, 2020
    Inventors: Peng HE, Xuechao WANG, Ta DENG, Hai ZHAO, Shuang CHEN, Haiyan LI, Guangxin DONG
  • FLUORINATED ETHER COMPOUND, FLUORINATED ETHER COMPOSITION, COATING LIQUID, ARTICLE AND ITS PRODUCTION METHOD
    Publication number: 20200165273
    Abstract: To provide a fluorinated ether compound, a fluorinated ether composition and a coating liquid capable of forming a surface layer excellent in initial water/oil repellency, fingerprint stain removability, abrasion resistance, light resistance and chemical resistance, an article having a surface layer, and a method for producing it. A fluorinated ether compound represented by A-O—(Rf1O)m—Rf2—SO2N(R1)(R2), wherein A is a C1-20 perfluoroalkyl group, Rf1 is a fluoroalkylene group, m is an integer of from 2 to 500, Rf2 is a fluoroalkylene group, R1 is a monovalent organic group having at least one hydrolyzable silyl group, R2 is a hydrogen atom, a monovalent organic group or a monovalent organic group having at least one hydrolyzable group, and the total number of the hydrolyzable silyl group(s) in R1 and the hydrolyzable group(s) in R2 is at least 2.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: AGC Inc.
    Inventors: Taiki HOSHINO, Eisuke MUROTANI, Keigo MATSUURA, Makoto UNO
  • NOVEL ISOCYANIDE COMPOUND AND HYDROSILYLATION REACTION CATALYST
    Publication number: 20200165274
    Abstract: Provided are a novel isocyanide compound, a hydrosilylation reaction catalyst having excellent handling properties and storage properties that allows a hydrosilylation reaction to proceed under moderate conditions by using the isocyanide compound, and a method for producing an addition compound by a hydrosilylation reaction using the hydrosilylation reaction catalyst. A hydrosilylation reaction catalyst prepared from a catalyst precursor comprising a transition metal compound of groups 8, 9, or 10 of the periodic table, excluding platinum, such as an iron carboxylate, cobalt carboxylate, or nickel carboxylate, and a ligand comprising an isocyanide compound having an organosiloxane group.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 28, 2020
    Applicants: SHIN-ETSU CHEMICAL CO., LTD., KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Koji SAKUTA, Hideo NAGASHIMA, Yusuke SUNADA, Daisuke NODA
  • COMPOUND HAVING ALKOXYSILYL GROUP AND ACTIVE ESTER GROUP, METHOD FOR PREPARING SAME, COMPOSITION COMPRISING SAME, AND USE
    Publication number: 20200165275
    Abstract: The present invention relates to a novel compound having an alkoxysilyl group and an active ester group, a method for preparing the same, a composition comprising the same, and a use, wherein the novel compound exhibits improved low moisture absorption and/or low dielectric properties when cured as an epoxy composition, but is not accompanied by loss of thermal expansion characteristics. Disclosed are a novel compound of formulae AF to LF having an alkoxysilyl group and an active ester group, and a method for preparing the same, a composition comprising the same, and a use of same.
    Type: Application
    Filed: June 5, 2017
    Publication date: May 28, 2020
    Inventors: Hyun-Aee CHUN, Yun-Ju KIM, Sook-Yeon PARK, Su-Jin PARK, Tae-Kwang KIM
  • NITROGEN-CONTAINING CYCLIC ORGANOXYSILANE COMPOUND AND METHOD FOR PRODUCING THE SAME
    Publication number: 20200165276
    Abstract: A nitrogen-containing cyclic organoxysilane compound having a formula (1): wherein R1 is a divalent hydrocarbon group. R2 is a monovalent hydrocarbon group or an organoxy group having a formula (2): —OR4??(2) wherein R4 is a monovalent hydrocarbon group, R3 is a divalent hydrocarbon group, A is a group having a formula (3) or (4): wherein each of R5 and R6 is a monovalent hydrocarbon group, a triorganosilyl group, or the like, R7 is a monovalent hydrocarbon group or triorganosilyl group, each of R8 and R9 is a divalent carbon atom having 1 to 20 carbon atoms, and R10 is C—H or a nitrogen atom, and E is an oxygen atom, a sulfur atom, or a group having a formula (5): wherein R3 is the same as described above, each of E1 and E2 independently is an oxygen atom or a sulfur atom, and n is an integer of 1 to 10.
    Type: Application
    Filed: November 14, 2019
    Publication date: May 28, 2020
    Applicant: SHIN-ETSU CHEMICAL CO., LTD.
    Inventor: Yoichi Tonomura
  • ISOCYANURIC ACID DERIVATIVE HAVING ALKOXYALKYL GROUPS AND METHOD FOR PRODUCING THE SAME
    Publication number: 20200165277
    Abstract: A novel isocyanuric acid derivative having two alkoxyalkyl groups and having a trialkoxysilyl group introduced therein, and a method for producing the isocyanuric acid derivative. An isocyanuric acid derivative of formula (1): wherein R1 is a methyl group or an ethyl group; two R2s are each a C1-2 alkylene group; and two R3s are each a methyl group, an ethyl group, or a C2-4 alkoxyalkyl group, which may be liquid at ambient temperature and ambient pressure.
    Type: Application
    Filed: May 29, 2018
    Publication date: May 28, 2020
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Shun KUBODERA, Yuichi GOTO, Wataru SHIBAYAMA, Gun SON
  • NOVEL HALOGERMANIDES AND METHODS FOR THE PREPARATION THEREOF
    Publication number: 20200165278
    Abstract: A trichlorogermanide of formula (I): [R4N]/[R4P]Cl[GeCl3] (I), where R is Me, Et, iPr, nBu, or Ph, tris(trichlorosilyl)germanide of formula (II): [R4N]/[RrP][Ge(SiCl3)3] (II), where R is Me, Et, iPr, nBu, or Ph, a tris(trichlorosilyl)germanide adduct of GaCl3 of formula (III): [Ph4P][Ge(SiCl3)3*GaCl3], and a tris(trichlorosilyl)germanide adduct of BBr3 of formula (IV): [Ph4P][Ge(SiCl3)3*BBr3]. Also, methods for preparing the trichlorogermanides of formula (I), the tris(trichlorosilyl)germanide of formula (II), the tris(trichlorosilyl)germanide adduct of BBr3 of formula (IV).
    Type: Application
    Filed: January 28, 2020
    Publication date: May 28, 2020
    Applicant: Evonik Degussa GmbH
    Inventors: Julian Teichmann, Matthias Wagner, Hans-Wolfram Lerner
  • PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA
    Publication number: 20200165279
    Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 28, 2020
    Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN
    Inventors: Dorothea BECKER, Thomas M. JOVIN, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV, Armin GIESE, Tiago F. OUTEIRO, Diana F. LAZARO, Michael P. SCHÖN, Margarete SCHÖN
  • MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20200165280
    Abstract: Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 28, 2020
    Inventors: Martha Alicia DE LA ROSA, Hongfeng DENG, Ghotas EVINDAR, Wieslaw Mieczyslaw KAZMIERSKI, John Franklin MILLER, Vicente SAMANO, Yoshiaki WASHIO, Bing XIA
  • BODIPY COMPOUNDS FOR USE IN DISPLAY DEVICES
    Publication number: 20200165281
    Abstract: Optionally substituted BODIPY-Iridium complexes, such as those depicted Formula 4, may be useful in filters for display devices.
    Type: Application
    Filed: June 5, 2018
    Publication date: May 28, 2020
    Inventor: Tissa Sajoto
  • TRIDENTATE IMINOPYRROLYL NICKEL COMPLEXES AND THEIR USE AS CATALYSTS FOR THE REACTION OF POLYMERISATION OF ETHYLENE TO HYPERBRANCHED POLYETHYLENE
    Publication number: 20200165282
    Abstract: The present invention relates to the preparation of novel nickel complexes containing iminopyrrolyl-type ligands, having the general molecular structure (I), and to their use as active catalysts in the polymerisation reaction of ethylene to hyperbranched polyethylene. The structure of the ligand precursor is such that it allows the occurrence of a cyclometallation reaction by the activation of a C—H bond, in the coordination reaction to the metal centre, generating a C,N,N?-tridentate complex.
    Type: Application
    Filed: June 20, 2018
    Publication date: May 28, 2020
    Applicant: INSTITUTO SUPERIOR TÉCNICO
    Inventors: Patrícia DA SILVA LOPES, Cláudia Alexandra CARICA FIGUEIRA, Pedro Manuel MACHADO TEIXEIRA GOMES
  • PROCESS
    Publication number: 20200165283
    Abstract: The present invention provides a metallocenyl compound of formula (I). Ra, Rb, Rc, Rd, Re, Rf, M, m, n, j, k, Y and Z and * are as described in the specification. The invention also provides a process for the preparation of the complexes, a process for increasing the optical purity of a compound of formula (II) and a process for the asymmetric transfer hydrogenation (ATH) of a metallocenyl compound of formula (V) to a metallocenyl compound of formula (IV).
    Type: Application
    Filed: July 4, 2018
    Publication date: May 28, 2020
    Inventors: Hans Guenter NEDDEN, Vaclav JURCIK, Garazi TALAVERA
  • METHOD FOR PREPARING CANAGLIFLOZIN AMORPHOUS FORM
    Publication number: 20200165284
    Abstract: Disclosed is a method for preparing a canagliflozin form. The method comprises the following steps: adding canagliflozin into an organic solvent and dissolving same, then distilling into a certain amount of an oil; then, adding an anti-solvent to the oil, stirring same with a precipitated solid, cooling, filtering, and drying to obtain the canagliflozin amorphous form. The preparation method has the characteristics of a low solvent ratio, a high yield, a simple operation, easy recovery, less three wastes and good producibility, with the resulting product having a stable quality, good fluidity, and being suitable for the preparation of formulations, etc., and the preparation process is easy to apply to large commercial production, and has a high value in terms of promotion and application.
    Type: Application
    Filed: February 6, 2018
    Publication date: May 28, 2020
    Inventors: Gang QIAN, Yanbao ZHOU, Linxiang ZHANG, Wenling ZHANG
  • PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDES
    Publication number: 20200165285
    Abstract: The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.
    Type: Application
    Filed: July 3, 2018
    Publication date: May 28, 2020
    Inventors: Laurence MULARD, Guillaume LE HEIGET, Zhaohu HU, Louis-Antoine BAREL, Isabelle ANDRE, Claire MOULIS, Magali REMAUD-SIMEON, Sophie BARBE, Mounir BENKOULOUCHE, Akli BEN IMEDDOURENE
  • TUNICAMYCIN ANALOGUES
    Publication number: 20200165286
    Abstract: The invention relates to tunicamycin analogues which are compounds according to Formula (I), or pharmaceutically acceptable salts thereof, (I) Wherein [Base] and R1 to R9 are as defined herein. The tunicamycin analogues are useful in the prevention or treatment of bacterial infection, in particular of tuberculosis.
    Type: Application
    Filed: June 6, 2018
    Publication date: May 28, 2020
    Inventors: Benjamin Guy DAVIS, Filip WYSZYNSKI, Hua WANG
  • SALT OF (SS)-ADENOSYL METHIONINE WITH INOSITOL HEXAPHOSPHATE, AND PROCESS FOR THE PREPARATION THEREOF
    Publication number: 20200165287
    Abstract: The invention relates to the salt of (SS)-adenosyl methionine with myo-inositol 1,2,3,4,5,6 hexakisphosphate, and pharmaceutical, nutraceutical or veterinary formulations containing it.
    Type: Application
    Filed: July 3, 2018
    Publication date: May 28, 2020
    Applicant: GNOSIS S.p.A.
    Inventors: Auro Roberto TAGLIANI, Daniele GREGORI, Davide BIANCHI, Marco BERNA, Federica COLZANI
  • COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY
    Publication number: 20200165288
    Abstract: This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that are useful, e.g., for treating a condition, disease or disorder in which a decrease or increase in STING activity (e.g., a decrease, e.g., a condition, disease or disorder associated with repressed or impaired STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 28, 2020
    Inventors: Gary Glick, Shomir Ghosh, Edward James Olhava, William R. Roush, Roger Jones
  • PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF OBETICHOLIC ACID AND DERIVATIVES THEREOF
    Publication number: 20200165289
    Abstract: A process for the preparation of obeticholic acid and derivatives thereof by: (a) hydrogenation of the double bond and reductive opening of the epoxide of a compound of formula (II) or a salt or solvate thereof to obtain a compound of formula (IIIa) and/or (IIIb), or salts or solvates thereof and (b) conversion of a compound of formula (IIIa) and/or a compound of formula (IIIb), or a salt or solvate thereof, into a compound of formula (I), or a salt or solvate thereof
    Type: Application
    Filed: June 22, 2018
    Publication date: May 28, 2020
    Inventors: Ignacio HERRÁIZ SIERRA, Yolanda FERNANDEZ SAINZ, Carlos CORDOVILLA LOSADA, Alfonso PÉREZ ENCABO, José Angel TURIEL HERNANDEZ
  • ISOTOPICALLY LABELED BILE ACID DERIVATIVES
    Publication number: 20200165290
    Abstract: The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof.
    Type: Application
    Filed: July 23, 2018
    Publication date: May 28, 2020
    Inventors: Gabriel GALVIN, Kevin SCHAAB, Mathew YANIK
  • NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF
    Publication number: 20200165291
    Abstract: Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 28, 2020
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • SYNTHESIS OF URSOLIC ACID NANOPARTICLES
    Publication number: 20200165292
    Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.
    Type: Application
    Filed: August 27, 2019
    Publication date: May 28, 2020
    Inventors: RABAB ABD EL MONEIM KHALIL EL DIB, SHAZA MOHAMED ADEL AL-MASSARANI, MANAL AHMED GASMELSEED AWAD, ALI ALI HASAN ELGAMAL
  • SYNTHESIS OF URSOLIC ACID NANOPARTICLES
    Publication number: 20200165293
    Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.
    Type: Application
    Filed: August 27, 2019
    Publication date: May 28, 2020
    Inventors: RABAB ABD EL MONEIM KHALIL EL DIB, SHAZA MOHAMED ADEL AL-MASSARANI, MANAL AHMED GASMELSEED AWAD, ALI ALI HASAN ELGAMAL
  • SYNTHESIS OF URSOLIC ACID NANOPARTICLES
    Publication number: 20200165294
    Abstract: The synthesis of ursolic acid nanoparticles includes dissolving ursolic acid powder in methanol, boiling water for five minutes, and adding the methanol solution to the boiled water dropwise at a flow rate of 0.1-0.3 ml/min under ultrasonic conditions. After sonication for 20 minutes, the contents are stirred for about 15 minutes, and then dried. Particle size distribution studies and TEM micrographs confirm the resulting product comprises nanoparticles. In vitro testing confirms the ursolic acid nanoparticles exhibit greater anticancer activity than conventional-size particles, and that the nanoparticles exhibit antimicrobial effect against gram positive and gram negative bacteria, as well as fungi.
    Type: Application
    Filed: August 27, 2019
    Publication date: May 28, 2020
    Inventors: RABAB ABD EL MONEIM KHALIL EL DIB, SHAZA MOHAMED ADEL AL-MASSARANI, MANAL AHMED GASMELSEED AWAD, ALI ALI HASAN ELGAMAL
  • METHOD FOR PURIFYING ANTI-IL-6 RECEPTOR ANTIBODIES
    Publication number: 20200165295
    Abstract: The present invention relates to a method for purifying anti-IL-6 receptor antibodies from a sample comprising said antibodies and impurities, through the use of a three-chromatographic columns procedure, including a chromatography on Fluorapatite-containing resin. The invention is also concerned with pharmaceutical compositions comprising the purified antibodies obtainable by the process of the invention.
    Type: Application
    Filed: August 30, 2018
    Publication date: May 28, 2020
    Inventors: Harry-James SUTTER, Xavier LE SAOUT
  • METHOD FOR IN VITRO GLYCOENGINEERING OF ANTIBODIES
    Publication number: 20200165296
    Abstract: Herein is reported a method for the enzymatic production of an antibody with a modified glycosylation in the Fc-region comprising the steps of incubating the antibody light chain affinity ligand-bound monoclonal antibody with a glycosylation in the Fc-region with a first enzyme for a time sufficient and under conditions suitable to modify the glycosylation of the Fc-region, recovering the antibody from the antibody light chain affinity ligand, incubating the recovered antibody in solution with a second enzyme for a time sufficient and under conditions suitable to modify the glycosylation of the Fc-region to a defined form, separating the antibody with the modified glycosylation in the Fc-region from the second enzyme in a cation exchange chromatography, and thereby producing the antibody with a modified glycosylation in the Fc-region.
    Type: Application
    Filed: June 20, 2019
    Publication date: May 28, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas DAMS, Roberto FALKENSTEIN, Sebastian MALIK, Ingrid GRUNERT, Marco Thomann, Matthias FREIHERR VON ROMAN, Heiko Walch
  • OPTIMIZED METHOD FOR ANTIBODY CAPTURING BY MIXED MODE CHROMATOGRAPHY
    Publication number: 20200165297
    Abstract: Herein is reported a method for the purification of an antibody directly captured from clarified cell culture supernatants using Streamline CST and/or Capto MMC, wherein especially product related (aggregates and fragments) and process related impurities (host cell protein, media components) could efficiently be removed, resulting in a preparation with a purity comparable to classical protein A affinity chromatography.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 28, 2020
    Inventors: Roberto Falkenstein, Thorsten Lemm, Markus Strasser, Hidenari Yamada
  • INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES
    Publication number: 20200165298
    Abstract: In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.
    Type: Application
    Filed: December 3, 2019
    Publication date: May 28, 2020
    Inventors: Sreerama SHETTY, Steven IDELL
  • COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20200165299
    Abstract: Methods treating pulmonary hypertension, including pulmonary arterial hypertension, are provided, and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Administration of the polypeptide antagonist reduces pulmonary artery acceleration time, reduces an amount of right ventricular hypertrophy, reduces right ventricular wall thickness, reduces an amount of pulmonary vessel wall thickness, reduces an amount of plexiform lesions in a lung of the subject, reduces an amount of collagen deposition in a pulmonary blood vessel, reduces an amount of collagen deposition in a pulmonary blood vessel media or adventitia, and/or reduces an amount of right ventricular fibrosis. Methods of reducing pulmonary vessel wall thickness are also provided and include the administration of the polypeptide antagonist of a Na/K ATPase/Src receptor complex.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 28, 2020
    Inventors: Zijian Xie, Jiayan Wang, Sandrine V. Pierre, Joseph I. Shapiro
  • Cyclic Peptides Targeting Alpha-4-Beta-7 Integrin
    Publication number: 20200165300
    Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.
    Type: Application
    Filed: November 14, 2016
    Publication date: May 28, 2020
    Inventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Adam Paul Kafal, James Gillard, Narendra Patel, Sai Kumar Chakka, Andrew L. Roughton, Marc-André Poupart, Gaoqiang Yang
  • ARTIFICIAL PROTEINS AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20200165301
    Abstract: De novo artificial protein based reporters that may be expressed in eukaryotic (e.g., mammalian) cells and methods of using the same are provided herein.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 28, 2020
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Goutham KODALI, Molly Marie SHEEHAN, Joshua MANCINI, Bohdana Marie DISCHER, Michael MAGARACI, Nathan M. ENNIST, Brian CHOW, Peter Leslie DUTTON, Christopher MOSER
  • MODIFIED VSV-G AND VACCINES THEREOF
    Publication number: 20200165302
    Abstract: A modified vesicular stomatitis virus glycoprotein (VSV-G) that includes at least one peptide, preferably an antigen or fragment thereof, nucleic acid sequence coding therefor, and vectors containing the nucleic acid sequence. Also vaccines and methods for the treatment of a disease or condition, in particular a cancer or an infectious disease.
    Type: Application
    Filed: September 14, 2017
    Publication date: May 28, 2020
    Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAIN
    Inventors: Gaëlle VANDERMEULEN, Laure LAMBRICHT, Véronique PRÉAT
  • Compositions and Methods Related to HIV-1 Immunogens
    Publication number: 20200165303
    Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
    Type: Application
    Filed: February 3, 2020
    Publication date: May 28, 2020
    Inventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
  • METHOD FOR MODIFYING RNA BINDING PROTEIN USING PPR MOTIF
    Publication number: 20200165304
    Abstract: The objects of the present invention are to identify the amino acids that play a principal role for the PPR motif to act as a RNA binding unit, as well as to provide a technology that regulates the RNA binding property thereof. The present invention provides a method for altering the RNA binding property of a PPR protein having one or more, preferably 2 or more, and more preferably 2-14 PPR motifs that consist of a polypeptide with a length of 30-38 amino acids, comprising a step of substituting one or more of the 1st, 4th, 8th, 9th, and 12th amino acids in the one or more PPR motifs with a different amino acid.
    Type: Application
    Filed: December 4, 2019
    Publication date: May 28, 2020
    Inventors: Takahiro Nakamura, Keiko Kobayashi
  • USE OF CGRP RECEPTOR ANTAGONISTS IN NEUROPROTECTION AND NEUROLOGICAL DISORDERS
    Publication number: 20200165305
    Abstract: Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.
    Type: Application
    Filed: August 30, 2017
    Publication date: May 28, 2020
    Inventor: Christopher Joseph Soares
  • Optically Transparent Silk Hydrogels
    Publication number: 20200165306
    Abstract: The present application relates to silk fibroin-based hydrogels, methods for making and using the same.
    Type: Application
    Filed: August 7, 2019
    Publication date: May 28, 2020
    Inventors: Fiorenzo G. Omenetto, David L. Kaplan, Benedetto Marelli, Alexander Nicholas Mitropolous
  • METHODS AND REAGENTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION
    Publication number: 20200165307
    Abstract: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.
    Type: Application
    Filed: November 6, 2019
    Publication date: May 28, 2020
    Inventor: Gregory S. Hageman
  • NETRIN- 1 AND DEPENDENCE RECEPTOR PROTEINS AND METHOD OF USE
    Publication number: 20200165308
    Abstract: Provided herein are fragments of Netrin-1 proteins, fragments of DCC proteins and NEO1 proteins, and antibodies to epitopes located within the fragments of Netrin-1, DCC, and/or NEO1. Also provided herein are methods for using the fragments and antibodies, including methods for inhibiting binding of Netrin-1 to an UNC5 protein, a DCC protein, and/or a NEO1 protein. Other methods provided herein include inducing apoptosis of a cell, and reducing formation of multimers of Netrin-1 proteins, and treating a subject having a cancer or at risk of having a cancer.
    Type: Application
    Filed: October 24, 2019
    Publication date: May 28, 2020
    Inventor: Jorg Stetefeld
  • ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES
    Publication number: 20200165309
    Abstract: The present disclosure describes the identification of a consensus formula representing ?-helical antimicrobial peptides (AHAPs) from broad classes of higher eukaryotes. Further provided are microbicidal peptides, compositions, methods, and uses, and computer systems and methods for identifying consensus formulae and for searching microbicidal peptides. In some embodiments, the peptide or fusion peptide includes one or more non-natural amino acid residues. Also provided is a composition comprising the ?-helical antimicrobial peptide or the fusion peptide, and a pharmaceutically acceptable carrier. Also provided is a method of treating an infection in a patient in need thereof, comprising administering to the patient an effective amount of a composition comprising an ?-helical antimicrobial peptide.
    Type: Application
    Filed: May 10, 2018
    Publication date: May 28, 2020
    Inventors: Nannette Y. Yount, Michael R. Yeaman
  • Colon and Pancreas Cancer Peptidomimetics
    Publication number: 20200165310
    Abstract: The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
    Type: Application
    Filed: November 27, 2019
    Publication date: May 28, 2020
    Inventor: Xue-Ping WANG
  • Polypeptide Solution, Production Method for Polypeptide Fiber, and Artificial Polypeptide
    Publication number: 20200165311
    Abstract: The present invention relates to a polypeptide solution in which polypeptide including an amino acid sequence derived from type I keratin that belongs to Cluster Ia is dissolved in a solvent including a formic acid or a solvent including an aprotic polar agent having a dipole moment of 3.0 D or more and an inorganic salt.
    Type: Application
    Filed: May 9, 2018
    Publication date: May 28, 2020
    Applicants: Spiber Inc., Kojima Industries Corporation
    Inventors: Ayumi Abe, Keisuke Morita, Kenji Kurachi, Yunosuke Abe
  • COSMETIC COMPOSITION FOR IMPROVING SKIN CONDITIONS COMPRISING FUSION PROTEIN INCLUDING SKIN PENETRATION ENHANCING PEPTIDE
    Publication number: 20200165312
    Abstract: Provided is a cosmetic composition for improving skin conditions including a fusion protein containing a skin penetration enhancing peptide, more particularly, a fusion protein in which PDGFa is bound to the skin penetration enhancing peptide, and a cosmetic composition for improving skin conditions, a functional cosmetic product for improving skin conditions, a cosmetic composition for preventing and treating alopecia, and a quasi-drug composition each including the fusion protein.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 28, 2020
    Applicant: LG HOUSEHOLD & HEALTH CARE LTD.
    Inventors: Jin Hyun KIM, Jaeyoon KIM, Ho Song CHO, Ji Seon YOON, Sanghwa LEE, Nae Gyu KANG, Hyun Jong LEE, Seol Hoon LEE, Eugene HUR, Taeyoon KIM
  • EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF
    Publication number: 20200165313
    Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
    Type: Application
    Filed: July 19, 2018
    Publication date: May 28, 2020
    Inventors: Jesper F. Lau, Florian Dismer, Kim Vilbour Andersen, Bhavesh Premdjee
  • Compositions and Methods of Use for Treating Metabolic Disorders
    Publication number: 20200165314
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Application
    Filed: February 7, 2020
    Publication date: May 28, 2020
    Inventors: Darrin Anthony Lindhout, Raj Haldankar, Hui Tian, Jer-Yuan Hsu
  • INSULIN-TRANSFERRIN FUSION PROTEIN AND ITS PRODRUG, PROINSULIN-TRANSFERRIN, FOR OVERCOMING INSULIN RESISTANCE
    Publication number: 20200165315
    Abstract: A method of treating Type 2 diabetes (T2D) is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes an insulin-transferrin fusion protein or its prodrug, proinsulin-transerrin fusion protein.
    Type: Application
    Filed: July 13, 2018
    Publication date: May 28, 2020
    Inventors: Wei-Chiang Shen, Yuqian Liu, Hsuan-Yao Wang
  • HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
    Publication number: 20200165316
    Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
    Type: Application
    Filed: February 11, 2020
    Publication date: May 28, 2020
    Inventors: Maria-Cristina LOOMIS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katherine Lee HENDRIX, Ethan W. OJALA, Pei FAN, Jeffrey T.L. SMITH, John A. LATHAM, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Vanessa Lisbeth RUBIN, Jens J. BILLGREN
  • METHODS AND COMPOSITIONS FOR PROTECTION AGAINST LENTIVIRAL INFECTIONS
    Publication number: 20200165317
    Abstract: The present invention provides methods and compositions for optimally co-expressing in a primate subject a tyrosylprotein sulfotransferase (TPST) and a lentiviral gp120-binding molecule to provide potent and long term protection against lentiviral infections.
    Type: Application
    Filed: February 11, 2020
    Publication date: May 28, 2020
    Inventors: Matthew Gardner, Michael Farzan
  • COMPOSITIONS COMPRISING D-AMINO ACID PEPTIDES AND METHODS OF PRODUCTION AND USE THEREOF FOR INHIBITING AUTOANTIBODIES
    Publication number: 20200165318
    Abstract: Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease, condition, or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.
    Type: Application
    Filed: November 27, 2019
    Publication date: May 28, 2020
    Inventor: David C. Kem